Short Interest in INVO Fertility, Inc (NASDAQ:IVF) Decreases By 65.8%

INVO Fertility, Inc (NASDAQ:IVF) was the recipient of a large drop in short interest in July. As of July 15th, there was short interest totaling 260,114 shares, a drop of 65.8% from the June 30th total of 760,242 shares. Based on an average daily volume of 358,678 shares, the short-interest ratio is currently 0.7 days. Approximately 14.6% of the shares of the stock are sold short.

Institutional Investors Weigh In On INVO Fertility

An institutional investor recently bought a new position in INVO Fertility stock. Citadel Advisors LLC bought a new stake in shares of INVO Fertility, Inc (NASDAQ:IVF) during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 1.19% of INVO Fertility as of its most recent filing with the SEC. 12.02% of the stock is owned by institutional investors.

INVO Fertility Price Performance

NASDAQ:IVF traded down $0.06 during mid-day trading on Monday, hitting $0.94. 82,677 shares of the company’s stock traded hands, compared to its average volume of 1,687,274. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.87 and a current ratio of 0.90. The company has a market cap of $1.68 million, a PE ratio of -0.00 and a beta of 2.28. The firm’s 50 day simple moving average is $1.45 and its 200 day simple moving average is $3.10. INVO Fertility has a 1 year low of $0.91 and a 1 year high of $90.80.

INVO Fertility (NASDAQ:IVF) last announced its quarterly earnings results on Monday, June 22nd. The company reported ($3.38) earnings per share (EPS) for the quarter. The business had revenue of $2.02 million during the quarter. INVO Fertility had a negative net margin of 183.75% and a negative return on equity of 420.62%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.